FULGENT GENETICS, INC. Income (Loss) from Equity Method Investments
FULGENT GENETICS, INC. (FLGT) reported Income (Loss) from Equity Method Investments of $143.00 thousand for the 3-month period ending 2020-12-31, per its 10-K filed 2022-02-28.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2023-02-28
- FULGENT GENETICS, INC. income (loss) from equity method investments for the quarter ending 2020-12-31 was $143.00K.
- FULGENT GENETICS, INC. income (loss) from equity method investments for the quarter ending 2020-09-30 was -$189.00K.
- FULGENT GENETICS, INC. income (loss) from equity method investments for the quarter ending 2020-06-30 was -$193.00K.
- FULGENT GENETICS, INC. income (loss) from equity method investments for the quarter ending 2020-03-31 was -$249.00K.
- FULGENT GENETICS, INC. income (loss) from equity method investments for fiscal 2020 was -$488.00K.
- FULGENT GENETICS, INC. income (loss) from equity method investments for fiscal 2019 was -$777.00K.
- FULGENT GENETICS, INC. income (loss) from equity method investments for fiscal 2018 was -$935.00K.
- FULGENT GENETICS, INC. income (loss) from equity method investments for fiscal 2017 was -$524.00K.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2020-12-31 | $143.00K 10-K · filed 2022-02-28 | -$46.00K derived: sum of 2 quarters · filed 2022-02-28 | -$239.00K derived: sum of 3 quarters · filed 2022-02-28 | -$488.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | -$189.00K 10-K · filed 2022-02-28 | -$382.00K derived: sum of 2 quarters · filed 2022-02-28 | -$631.00K 10-Q · filed 2021-11-09 | -$805.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$193.00K 10-K · filed 2022-02-28 | -$442.00K 10-Q · filed 2021-08-10 | -$616.00K derived: sum of 3 quarters · filed 2022-02-28 | -$791.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$249.00K 10-K · filed 2022-02-28 | -$423.00K derived: sum of 2 quarters · filed 2022-02-28 | -$598.00K derived: sum of 3 quarters · filed 2022-02-28 | -$747.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$174.00K 10-K · filed 2021-03-08 | -$349.00K derived: sum of 2 quarters · filed 2021-03-08 | -$498.00K derived: sum of 3 quarters · filed 2021-03-08 | -$777.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | -$175.00K 10-K · filed 2021-03-08 | -$324.00K derived: sum of 2 quarters · filed 2021-03-08 | -$603.00K 10-Q · filed 2020-11-09 | -$837.00K derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-06-30 | -$149.00K 10-K · filed 2021-03-08 | -$428.00K 10-Q · filed 2020-08-05 | -$662.00K derived: sum of 3 quarters · filed 2021-03-08 | -$872.00K derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-03-31 | -$279.00K 10-K · filed 2021-03-08 | -$513.00K derived: sum of 2 quarters · filed 2021-03-08 | -$723.00K derived: sum of 3 quarters · filed 2021-03-08 | -$969.00K derived: sum of 4 quarters · filed 2021-03-08 |
| 2018-12-31 | -$234.00K 10-K · filed 2020-03-13 | -$444.00K derived: sum of 2 quarters · filed 2020-03-13 | -$690.00K derived: sum of 3 quarters · filed 2020-03-13 | -$935.00K 10-K · filed 2020-03-13 |
| 2018-09-30 | -$210.00K 10-K · filed 2020-03-13 | -$456.00K derived: sum of 2 quarters · filed 2020-03-13 | -$701.00K 10-Q · filed 2019-11-08 | -$948.00K derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-06-30 | -$246.00K 10-K · filed 2020-03-13 | -$491.00K 10-Q · filed 2019-08-12 | -$738.00K derived: sum of 3 quarters · filed 2020-03-13 | -$910.00K derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-03-31 | -$245.00K 10-K · filed 2020-03-13 | -$492.00K derived: sum of 2 quarters · filed 2020-03-13 | -$664.00K derived: sum of 3 quarters · filed 2020-03-13 | -$769.00K derived: sum of 4 quarters · filed 2020-03-13 |
| 2017-12-31 | -$247.00K 10-K · filed 2019-03-22 | -$419.00K derived: sum of 2 quarters · filed 2019-03-22 | -$524.00K derived: sum of 3 quarters · filed 2019-03-22 | -$524.00K 10-K · filed 2019-03-22 |
| 2017-09-30 | -$172.00K 10-K · filed 2019-03-22 | -$277.00K derived: sum of 2 quarters · filed 2019-03-22 | -$277.00K 10-Q · filed 2018-11-09 | -$277.00K derived: sum of 4 quarters · filed 2019-03-22 |
| 2017-06-30 | -$105.00K 10-K · filed 2019-03-22 | -$105.00K 10-Q · filed 2018-08-13 | -$105.00K derived: sum of 3 quarters · filed 2019-03-22 | -$105.00K derived: sum of 4 quarters · filed 2019-03-22 |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-14 | $0.00 derived: sum of 2 quarters · filed 2018-05-14 | $0.00 derived: sum of 3 quarters · filed 2018-05-14 | $0.00 derived: sum of 4 quarters · filed 2018-05-14 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | $0.00 derived: sum of 2 quarters · filed 2018-03-20 | $0.00 derived: sum of 3 quarters · filed 2018-03-20 | $0.00 10-K · filed 2018-03-20 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-13 | $0.00 derived: sum of 2 quarters · filed 2017-11-13 | $0.00 10-Q · filed 2017-11-13 | |
| 2016-06-30 | $0.00 10-Q · filed 2017-08-14 | $0.00 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |